Although the TGF-β1 signaling has been proven as a predictive marker and pharmacological target for IPF, few anti-fibrotic drugs targeting this signaling are put into clinical use due to side effects and the need for large doses (Shi et al., 2022). Here, TGFB1 is linked to idiopathic pulmonary fibrosis.